Among the 8 patients with AML, that were assessed, only 1 patient exhibited a response to CT-011, a humanized antibody interacting with PD-1, demonstrating a reduction in peripheral blood blasts from 50% to 5% and remaining free from platelet transfusions for 9 months (10). Here, PDCD1 is linked to acute myeloid leukemia.